Trial reportBMC musculoskeletal disorders2026
Liposomal bupivacaine in peri-articular injection reduces opioid consumption and improves early prognosis of total knee arthroplasty: a randomized controlled trial.
Trial report in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTotal knee arthroplasty (TKA) has become a common surgical procedure for alleviating pain caused by end-stage osteoarthritis and improving joint dysfunction, but the optimal postoperative analgesic regimen remains controversial. This study aimed to evaluate the efficacy and safety of liposomal bupivacaine(LB) for peri-articular injection (PAI) in TKA, focusing on its impact on early postoperative outcomes, and comparing it with traditional ropivacaine hydrochloride (RH).
methodsFrom February to June 2025, 121 patients undergoing total knee arthroplasty at Qingdao University Affiliated Hospital were enrolled. This single-center, parallel-group, double-blind study randomly assigned patients in a 1:1 ratio using a random number table to the LB or RH group. Prime outcomes include the visual analogue scale (VAS) within 72 h after surgery and the consumption of opioid drugs. Secondary outcomes comprised postoperative knee range of motion (ROM), time to first ambulation (TFA), Timed Up-and-Go (TUG) test, 2-minute walk test(2MWT), length of hospital stay (LHT), and postoperative adverse events.
resultsDemographic and clinical characteristics were comparable between groups. The LB group demonstrated lower postoperative pain scores and opioid consumption. Additionally, LB group patients exhibited markedly greater joint range of motion and earlier time to first ambulation compared to the RH group. The incidence of adverse events was similar between groups. One patient in the LB group and two in the RH group experienced early postoperative complications, none of which were considered related to analgesic selection.
conclusionThis study demonstrates that LB may alleviate postoperative knee pain, reduce the consumption of opioid drugs, and thereby facilitate recovery.
trial registrationClinicaltrials.gov. Identifier ChiCTR2400082998, 12/04/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.